Literature DB >> 9572901

Formation of isomorphic desolvates: creating a molecular vacuum.

G A Stephenson1, E G Groleau, R L Kleemann, W Xu, D R Rigsbee.   

Abstract

The objective of this work was to investigate a common but poorly understood category of crystalline organic substances: isomorphic desolvates. When solvent is lost from a crystal lattice but the lattice retains its three-dimensional order, a lattice is created which is in a high-energy state relative to the original solvate structure. The desolvated lattice can reduce its internal energy by either resorbing solvent or by relaxation processes which increase the packing efficiency of the solid by reducing the unit cell volume. In the following paper, solid-state properties of isomorphic desolvates of cephalexin, cefaclor, erythromycin A, and spirapril hydrochloride hydrates are investigated. The hygroscopicity of the compounds are evaluated using a vacuum moisture balance, and structural relaxation is measured using a combination of X-ray powder diffraction and isothermal microcalorimetry. The study results are explained in terms of Kitaigorodski's close packing principle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572901     DOI: 10.1021/js970449z

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Influence of moisture on the crystal forms of niclosamide obtained from acetone and ethyl acetate.

Authors:  Rahul V Manek; William M Kolling
Journal:  AAPS PharmSciTech       Date:  2004-03-04       Impact factor: 3.246

2.  The role of molecular structure in the crystal polymorphism of local anesthetic drugs: crystal polymorphism of local anesthetic drugs, part X.

Authors:  Andrea C Schmidt
Journal:  Pharm Res       Date:  2005-11-16       Impact factor: 4.200

3.  Crystal morphology engineering of pharmaceutical solids: tabletting performance enhancement.

Authors:  Sabiruddin Mirza; Inna Miroshnyk; Jyrki Heinämäki; Osmo Antikainen; Jukka Rantanen; Pia Vuorela; Heikki Vuorela; Jouko Yliruusi
Journal:  AAPS PharmSciTech       Date:  2009-01-30       Impact factor: 3.246

4.  Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 2: Safety considerations of impurities in pharmaceutical products and surveying the impurity landscape.

Authors:  Karen M Alsante; Kim C Huynh-Ba; Steven W Baertschi; Robert A Reed; Margaret S Landis; Scott Furness; Bernard Olsen; Mark Mowery; Karen Russo; Robert Iser; Gregory A Stephenson; Patrick Jansen
Journal:  AAPS PharmSciTech       Date:  2013-12-21       Impact factor: 3.246

5.  Solid-State and Solution Characterization of Myricetin.

Authors:  Stephen J Franklin; Paul B Myrdal
Journal:  AAPS PharmSciTech       Date:  2015-05-19       Impact factor: 3.246

6.  Influence of solvents on the variety of crystalline forms of erythromycin.

Authors:  Sabiruddin Mirza; Inna Miroshnyk; Jyrki Heinämäki; Leena Christiansen; Milja Karjalainen; Jouko Yliruusi
Journal:  AAPS PharmSci       Date:  2003

7.  Instability in theophylline and carbamazepine hydrate tablets: cocrystal formation due to release of lattice water.

Authors:  Kapildev K Arora; Seema Thakral; Raj Suryanarayanan
Journal:  Pharm Res       Date:  2013-04-09       Impact factor: 4.200

8.  Rapid insight into heating-induced phase transformations in the solid state of the calcium salt of atorvastatin using multivariate data analysis.

Authors:  Niels Peter Aae Christensen; Bernard Van Eerdenbrugh; Kaho Kwok; Lynne S Taylor; Andrew D Bond; Thomas Rades; Jukka Rantanen; Claus Cornett
Journal:  Pharm Res       Date:  2012-11-10       Impact factor: 4.200

9.  Navigating the Waters of Unconventional Crystalline Hydrates.

Authors:  Doris E Braun; Lien H Koztecki; Jennifer A McMahon; Sarah L Price; Susan M Reutzel-Edens
Journal:  Mol Pharm       Date:  2015-06-30       Impact factor: 4.939

10.  Stoichiometric and Non-Stoichiometric Hydrates of Brucine.

Authors:  Doris E Braun; Ulrich J Griesser
Journal:  Cryst Growth Des       Date:  2016-08-26       Impact factor: 4.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.